Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board

Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s Scientific Advisory Board and will chair the company’s Clinical Advisory Board. Astrocyte Pharmaceuticals is developing small molecule therapeutics for the treatment of brain injuries, including patients who have suffered a stroke, traumatic brain injury (TBI) or concussion.

“Dr. Saver is a recognized international thought leader on cerebrovascular research and treatments, with impressive experience in designing and leading multiple, successful, innovative clinical studies in stroke,” said William Korinek, CEO at Astrocyte Pharmaceuticals.  “We are excited to have Dr. Saver chair our Clinical Advisory Board that will design the optimal clinical studies to assess AST-004’s efficacy in human patients.”

Dr. Jeffrey Saver is Vice-Chair and Professor of Neurology at the David Geffen School of Medicine at UCLA and has been the Director of the UCLA Stroke Unit since its inception in 1995.  He is a global leader in cerebrovascular research and clinical care, with research across stroke prevention, stroke diagnosis, acute stroke treatment, and neurocognitive and neurobehavioral consequences of stroke.  Dr. Saver has published more than 500 original articles, more than 30 book chapters, and two edited volumes, and is currently associate editor at JAMA, the Journal of the American Medical Association, and consulting editor at the journal Stroke.   Dr. Saver has been the global or site principal investigator for more than 50 clinical research studies including the groundbreaking studies FAST-MAG, SWIFT-PRIME, and DAWN.

“Stroke clinical research has advanced tremendously in the past decade, with enhanced potential to evaluate novel therapeutic agents,” said Dr. Saver.  “AST-004 had demonstrated promising data in preclinical studies and has the potential to benefit hundreds of thousands of patients who suffer a stroke each year.”

For more information about Astrocyte Pharmaceuticals please contact Dr. William Korinek at 617-444-8765 or


About Astrocyte Pharmaceuticals Inc.
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.